HCM KYG4672N1198

Rapport

Vertraagde tijd London Stock Exchange - 17:35 27-06-2022
215.00	GBX		+1.42%

01/06	HUTCHMED krijgt goedkeuring van de overheid voor het gebruik van het oncologisch geneesmiddel Tazverik in de Chinese pilootzone voor medisch toerisme Hainan	MT
01/06	HUTCHMED kondigt aan dat TAZVERIK(R) goedgekeurd is voor gebruik in Hainan Pilot Zone in China	CI
17/05	Aziatische ADR's stijgen in de dinsdaghandel	MT

Nieuws

Aanbevelingen van analisten

Andere talen

Persberichten

Officiële publicaties

Sectornieuws

Communiqués de presse de la société HUTCHMED (CHINA) LIMITED

13:55	HUTCHMED CHINA : to Announce 2022 Half-Year Financial Results - Form 6-K	PU
10:30	HUTCHMED to Announce 2022 Half-Year Financial Results	AQ
01/06	HUTCHMED CHINA : Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - F..	PU
24/05	HUTCHMED CHINA : - Form 6-K	PU
16/05	Appointment of Non–Executive Director	AQ
02/05	HUTCHMED CHINA : INSIDE INFORMATION - Form 6-K	PU
27/04	HUTCHMED CHINA : Annual General Meeting held on April 27, 2022 – Poll Results - Form..	PU
21/04	HUTCHMED CHINA : Vesting of awards under the Long Term Incentive Plan - Form 6-K	PU
31/03	HUTCHMED CHINA : Update on Status under Holding Foreign Companies Accountable Act - Form 6..	PU
31/03	Update on Status under Holding Foreign Companies Accountable Act	AQ
23/03	HUTCHMED CHINA : Annual Report and Notice of Annual General Meeting - Form 6-K	PU
11/03	HUTCHMED CHINA : Update on Status under Holding Foreign Companies Accountable Act - Form 6..	PU
09/03	HUTCHMED CHINA : Vesting of awards under the Long Term Incentive Plan - Form 6-K	PU
07/03	HUTCHMED CHINA : Receives a US$15 million Milestone from AstraZeneca for Initiating Start-..	PU
07/03	HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Ac..	AQ
03/03	HUTCHMED CHINA : Reports 2021 Full Year Results and Provides Business Updates - Form 6-K	PU
03/03	HUTCHMED CHINA : - Form 6-K	PU
03/03	HUTCHMED announces retirement of CEO and appointment of new CEO	AQ
03/03	HUTCHMED Reports 2021 Full Year Results and Provides Business Updates	AQ
01/03	HUTCHMED CHINA : Receives Approval to Commercialize ELUNATE® in Macau - Form 6-K	PU
01/03	HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau	AQ
07/02	HUTCHMED CHINA : to Announce 2021 Final Results - Form 6-K	PU
07/02	HUTCHMED to Announce 2021 Final Results	AQ
04/02	HUTCHMED CHINA : Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy ..	PU
04/02	HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or To..	AQ
20/01	HUTCHMED CHINA : Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant..	PU
20/01	HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Soli..	AQ
19/01	HUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..	PU
19/01	HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastroi..	AQ
18/01	TR-1 : Standard form for notification of major holdings - Form 6-K	PU
12/01	HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for HMPL-523 for Trea..	PU
10/01	HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..	PU
10/01	HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..	AQ
03/01	HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K	PU
2021	HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K	PU
2021	HUTCHMED Included in FTSE Russell Indexes	AQ
2021	HUTCHMED CHINA : - Form 6-K	PU
2021	HUTCHMED CHINA : Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meetin..	PU
2021	HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting	AQ
2021	HUTCHMED CHINA : Highlights Surufatinib and Toripalimab Combination Clinical Data being Pr..	PU
2021	HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Present..	AQ
2021	HUTCHMED CHINA : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fru..	PU
2021	HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquint..	AQ
2021	HUTCHMED CHINA : Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Add..	PU
2021	HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition..	AQ
2021	HUTCHMED CHINA : and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO®..	PU
2021	HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Comb..	AQ
2021	Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now avail..	AQ
2021	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Vi..	AQ
2021	HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..	PU
2021	HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..	AQ
2021	HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..	PU
2021	HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..	AQ
2021	HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..	PU
2021	HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..	AQ
2021	HUTCHMED CHINA : Grant of Awards under Long Term Incentive Plan - Form 6-K	PU
2021	HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture (Form 6-K)	PU
2021	HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture	AQ
2021	HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..	PU
2021	HUTCHMED CHINA : Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with T..	AQ
2021	HUTCHMED CHINA : — Following surufatinib launch in China in January 2021; NDA accept..	PU
2021	HUTCHMED CHINA : Initiates a Japan Bridging Study to Support Surufatinib Registration for ..	AQ
2021	HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..	PU
2021	HUTCHMED CHINA : Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-..	AQ
2021	HUTCHMED CHINA : — Follows important findings from the SAVANNAH study of this combin..	PU
2021	HUTCHMED CHINA : Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-..	PU
2021	HUTCHMED CHINA : Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtua..	AQ
2021	HUTCHMED CHINA : Grant of Share Options under Share Option Scheme and Awards under Long Te..	PU
2021	HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..	PU
2021	HUTCHMED CHINA : Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tisleli..	AQ
2021	HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes (Form 6-K)	PU
2021	HUTCHMED CHINA : Selected as Constituent of Certain Hang Seng Indexes	AQ
2021	EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVE..	AQ
2021	HUTCHMED CHINA : Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Comm..	BU
2021	HUTCHMED CHINA : Reports 2021 Interim Results and Provides Business Updates (Form 6-K)	PU

1 2 Volgende

Volgende evenement op HUTCHMED (CHINA) LIMITED

03/08/22

Eerste halfjaar 2022 Cijferpublicaties (schatting)

De agenda van het bedrijf

Komende gebeurtenissen in de sector

19/07/22	JOHNSON & JOHNSON : Eerste halfjaar 2022 Cijferpublicaties
21/07/22	ROCHE HOLDING AG : Eerste halfjaar 2022 Cijferpublicaties
28/07/22	PFIZER INC. : Eerste halfjaar 2022 Cijferpublicaties
29/07/22	ABBVIE INC. : Eerste halfjaar 2022 Cijferpublicaties (schatting)

Meer evenementen

Sector

Gezondheidszorg
	Farmaceutisch en medisch onderzoek
		Farmaceutische producten
			Farmaceutische producten
				Farmaceutische producten - Andere